Literature DB >> 6712860

Changes in blood chemistry in hypertensive patients during propranolol therapy.

F Andreasen, P Jakobsen, H J Kornerup, E B Pedersen, O L Pedersen, J Weeke.   

Abstract

Propranolol induced changes in blood plasma chemistry were followed in thirty hypertensive patients (WHO I-II) who were seen each week during 14-15 weeks. The initial 4 weeks were a drug free period and the next 2 weeks were a drug adjustment period. After that the patients were on an unchanged propranolol dose for 8 weeks (40, 80 or 160 mg four times daily). For all observed changes the correlation was studied to (1) dose, (2) free and total simultaneously determined plasma concentration and (3) free and total average plasma concentration of unchanged drug during the preceding 24 h period. Total protein and albumin did not change significantly. After 4 and 8 weeks on the final dose orosomucoid was increased significantly (by 10%) compared with the value from the end of the drug free period. Creatinine rose significantly during the initial 4-6 weeks therapy to remain at the same level during the last 4 weeks. Urate was increased at the two lowest dose levels. Total cholesterol fell significantly (5%) while triglycerides increased significantly (16%). T4 rose significantly, T3 fell and r-T3 rose significantly in a dose dependent way. Interindividually r-T3 was the only biochemical change showing a significant relationship to the propranolol plasma concentration. The relationship reached the highest level of significance to the average 24 h free concentration.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6712860      PMCID: PMC1463379          DOI: 10.1111/j.1365-2125.1984.tb02341.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  21 in total

1.  Variable binding of propranolol in human serum.

Authors:  G Sager; O G Nilsen; S Jacobsen
Journal:  Biochem Pharmacol       Date:  1979-03-15       Impact factor: 5.858

2.  Propranolol binding to serum orosomucoid.

Authors:  B J Scott; A R Bradwell; R E Schneider; H Bishop
Journal:  Lancet       Date:  1979-04-28       Impact factor: 79.321

3.  Quantitative estimation of proteins by electrophoresis in agarose gel containing antibodies.

Authors:  C B Laurell
Journal:  Anal Biochem       Date:  1966-04       Impact factor: 3.365

4.  Metabolic consequences of atenolol and propranolol in treatment of essential hypertension.

Authors:  J L Day; N Simpson; J Metcalfe; R L Page
Journal:  Br Med J       Date:  1979-01-13

5.  Serum potassium and uric acid changes during treatment with timolol alone and in combination with a diuretic.

Authors:  O L Pedersen; E Mikkelsen
Journal:  Clin Pharmacol Ther       Date:  1979-09       Impact factor: 6.875

6.  Increased plasma protein binding of propranolol and chlorpromazine mediated by disease-induced elevations of plasma alpha1 acid glycoprotein.

Authors:  K M Piafsky; O Borgá; I Odar-Cederlöf; C Johansson; F Sjöqvist
Journal:  N Engl J Med       Date:  1978-12-28       Impact factor: 91.245

7.  Radioimmunological determination of reverse triiodothyronine in unextracted serum and serum dialysates.

Authors:  P Laurberg; J Weeke
Journal:  Scand J Clin Lab Invest       Date:  1977-12       Impact factor: 1.713

Review 8.  Propranolol in the treatment of thyrotoxicosis: a review.

Authors:  D G McDevitt
Journal:  Postgrad Med J       Date:  1976       Impact factor: 2.401

9.  Inhibition by propranolol of 3,5,3'-triiodothyronine formation from thyroxine in isolated rat renal tubules: an effect independent of beta-adrenergic blockade.

Authors:  P Heyma; R G Larkins; D G Campbell
Journal:  Endocrinology       Date:  1980-05       Impact factor: 4.736

10.  Effect of propranolol and prazosin on blood lipids. The Oslo Study.

Authors:  P Leren; P O Foss; A Helgeland; I Hjermann; I Holme; P G Lund-Larsen
Journal:  Lancet       Date:  1980-07-05       Impact factor: 79.321

View more
  1 in total

1.  Comparison of the efficacy and acceptability of nicardipine and propranolol, alone and in combination, in mild to moderate hypertension.

Authors:  D Maclean; E T Mitchell; E M Laing; F C Macdonald; K J Gough; R J Dow; D G McDevitt
Journal:  Br J Clin Pharmacol       Date:  1989-05       Impact factor: 4.335

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.